Literature DB >> 28685000

Amphotericin B potentiates the anticancer activity of doxorubicin on the MCF-7 breast cancer cells.

Farzaneh Tavangar1, Hamid Sepehri2, Marie Saghaeian Jazi3, Jahanbakhsh Asadi4.   

Abstract

Despite the improvements in cancer treatment, breast cancer still remains the second most common cause of death from cancer in women. Doxorubicin (DOXO) is widely used for cancer treatment. However, drug resistance limits the treatment outcome. Here, we investigated the toxicity of DOXO in combination with an antifungal agent amphotericin B (AmB) against the MCF-7 breast cancer cell line. The cell viability was measured using MTT assay. The apoptosis was studied by caspase-8 and caspase-9 activity measurements and DNA fragmentation was investigated by TUNEL assay. The combination of two drugs significantly increased the apoptotic index and the caspase-8 and caspase-9 activities in comparison to DOXO-treated cells. Our finding showed that pre-treatment of MCF-7 cells with AmB synergistically exerted the anticancer effect of DOXO through the caspase-dependent apoptosis manner.

Entities:  

Keywords:  Amphotericin B; Apoptosis; Caspase; Doxorubicin; MCF-7 breast cancer cell line

Year:  2017        PMID: 28685000      PMCID: PMC5480266          DOI: 10.1007/s12154-017-0172-1

Source DB:  PubMed          Journal:  J Chem Biol        ISSN: 1864-6158


  36 in total

Review 1.  Ion homeostasis and apoptosis.

Authors:  S P Yu; L M Canzoniero; D W Choi
Journal:  Curr Opin Cell Biol       Date:  2001-08       Impact factor: 8.382

Review 2.  A simple and reliable approach for assessing anticancer activity in vitro.

Authors:  Miguel López-Lázaro
Journal:  Curr Med Chem       Date:  2015       Impact factor: 4.530

Review 3.  Apoptotic cell signaling in cancer progression and therapy.

Authors:  Jessica Plati; Octavian Bucur; Roya Khosravi-Far
Journal:  Integr Biol (Camb)       Date:  2011-02-22       Impact factor: 2.192

Review 4.  Lysosomes as targets for cancer therapy.

Authors:  Nicole Fehrenbacher; Marja Jäättelä
Journal:  Cancer Res       Date:  2005-04-15       Impact factor: 12.701

5.  Effect of amphotericin B on Adriamycin transport in P388 cells.

Authors:  A Krishan; A Sauerteig; K Gordon
Journal:  Cancer Res       Date:  1985-09       Impact factor: 12.701

6.  Amphotericin B-induced renal tubular cell injury is mediated by Na+ Influx through ion-permeable pores and subsequent activation of mitogen-activated protein kinases and elevation of intracellular Ca2+ concentration.

Authors:  Takahisa Yano; Yoshinori Itoh; Eiko Kawamura; Asuka Maeda; Nobuaki Egashira; Motohiro Nishida; Hitoshi Kurose; Ryozo Oishi
Journal:  Antimicrob Agents Chemother       Date:  2009-01-12       Impact factor: 5.191

7.  Two mechanisms of synergism when amphotericin B is used in combination with actinomycin D or 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea against the human promyelocytic leukemia cell line HL-60.

Authors:  A Vertut-Croquin; J Brajtburg; G Medoff
Journal:  Cancer Res       Date:  1986-12       Impact factor: 12.701

8.  Doxorubicin Changes Bax /Bcl-xL Ratio, Caspase-8 and 9 in Breast Cancer Cells.

Authors:  Simin Sharifi; Jaleh Barar; Mohammad Saeid Hejazi; Nasser Samadi
Journal:  Adv Pharm Bull       Date:  2015-09-19

9.  Taiwanofungus camphoratus (Syn Antrodia camphorata) extract and amphotericin B exert adjuvant effects via mitochondrial apoptotic pathway.

Authors:  Ling-Yi Chen; Ming-Thau Sheu; Chuh-Kai Liao; Feng-Chou Tsai; Woei-Yao Kao; Ching-Hua Su
Journal:  Integr Cancer Ther       Date:  2012-07-12       Impact factor: 3.279

10.  Inhibitory and apoptosis-inducing effects of Newcastle disease virus strain AF2240 on mammary carcinoma cell line.

Authors:  Umar Ahmad; Ismaila Ahmed; Yong Yoke Keong; Nizar Abd Manan; Fauziah Othman
Journal:  Biomed Res Int       Date:  2015-03-02       Impact factor: 3.411

View more
  1 in total

1.  Dacarbazine nanoparticle topical delivery system for the treatment of melanoma.

Authors:  Abdul Hafeez; Imran Kazmi
Journal:  Sci Rep       Date:  2017-11-28       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.